A retrospective, observational study analysing efficacy of Polatuzumab-vedotin in a real-world setting in r/r Large B-Cell Lymphoma
Latest Information Update: 05 Jan 2021
At a glance
- Drugs Polatuzumab vedotin (Primary) ; Antineoplastics; Bendamustine; CAR-T cell therapies; Cyclophosphamide; Doxorubicin; Gemcitabine; Immunotherapies; Prednisone; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 05 Jan 2021 New trial record
- 08 Dec 2020 Results (as of July 22nd, 2020; n=97) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology